Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma.
Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Sabatelli L, Waltl EE, Winderlich M, Sporchia A, Kurukulasuriya NC, Cordoba R, Hess G, Salles G. Nowakowski GS, et al. Among authors: fleury i. Ann Hematol. 2023 Sep;102(9):2643-2644. doi: 10.1007/s00277-023-05321-3. Ann Hematol. 2023. PMID: 37432417 Free PMC article. No abstract available.
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.
Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, Jäger U, Cartron G, Izutsu K, Dreyling M, Kahl B, Ghesquieres H, Ardeshna K, Goto H, Barbui AM, Abramson JS, Borchmann P, Fleury I, Mielke S, Skarbnik A, de Vos S, Kamdar M, Karmali R, Viardot A, Farazi T, Fasan O, Lymp J, Vedal M, Nishii R, Avilion A, Papuga J, Kumar J, Nastoupil LJ. Morschhauser F, et al. Among authors: fleury i. Nat Med. 2024 Aug;30(8):2199-2207. doi: 10.1038/s41591-024-02986-9. Epub 2024 Jun 3. Nat Med. 2024. PMID: 38830991 Free PMC article. Clinical Trial.
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, Rapoport AP, Sureda A, Jacobson CA, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie LA, Chaganti S, Dickinson M, Dorritie K, Reagan PM, McGuirk J, Song KW, Riedell PA, Minnema MC, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani SA, Schupp M, To C, Locke FL; ZUMA-7 Investigators; Kite Members. Westin JR, et al. N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665. Epub 2023 Jun 5. N Engl J Med. 2023. PMID: 37272527 Clinical Trial.
Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma.
Lemieux C, Ahmad I, Bambace NM, Bernard L, Cohen S, Delisle JS, Fleury I, Kiss T, Mollica L, Roy DC, Sauvageau G, Roy J, Lachance S. Lemieux C, et al. Among authors: fleury i. Biol Blood Marrow Transplant. 2020 Jan;26(1):157-161. doi: 10.1016/j.bbmt.2019.09.007. Epub 2019 Sep 12. Biol Blood Marrow Transplant. 2020. PMID: 31521818 Free article. Clinical Trial.
Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy.
Liu J, Stewart D, Fontaine A, Peters A, Fleury I, Mollica L, Prica A, Buckstein R, Sehn L, Jiang A, Kuruvilla J, Villa D. Liu J, et al. Among authors: fleury i. Leuk Lymphoma. 2020 Oct;61(10):2492-2496. doi: 10.1080/10428194.2020.1772472. Epub 2020 Jun 10. Leuk Lymphoma. 2020. PMID: 32519592 No abstract available.
Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective.
Veilleux O, Claveau JS, Alaoui H, Roy J, Ahmad I, Delisle JS, Kiss T, Bambace NM, Bernard L, Cohen S, Sauvageau G, Fleury I, Mollica L, Roy DC, Serroukh Y, Lachance S. Veilleux O, et al. Among authors: fleury i. Transplant Cell Ther. 2022 Mar;28(3):145-151. doi: 10.1016/j.jtct.2021.12.005. Epub 2021 Dec 23. Transplant Cell Ther. 2022. PMID: 34954149 Free article.
Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge.
Lachance S, Bourguignon A, Boisjoly JA, Bouchard P, Ahmad I, Bambace N, Bernard L, Cohen S, Delisle JS, Fleury I, Kiss T, Mollica L, Roy DC, Sauvageau G, Veilleux O, Zehr J, Chagnon M, Roy J. Lachance S, et al. Among authors: fleury i. Transplant Cell Ther. 2023 Jan;29(1):34.e1-34.e7. doi: 10.1016/j.jtct.2022.10.003. Epub 2022 Oct 12. Transplant Cell Ther. 2023. PMID: 36243319 Free article.
44 results